Ausgabe 1/2017
Inhalt (24 Artikel)
Rituximab to treat gemcitabine-induced hemolytic–uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review
Georgia E. Ritchie, Mangalee Fernando, David Goldstein
Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial
Michel Ducreux, Jaafar Bennouna, Antoine Adenis, Thierry Conroy, Astrid Lièvre, Fabienne Portales, Julie Jeanes, Li Li, Alfredo Romano
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors
James Spicer, Sheeba Irshad, Joo Ern Ang, Deborah Enting, Rebecca Kristeleit, Martina Uttenreuther-Fischer, Karine Pemberton, Katy Pelling, David Schnell, Johann de Bono
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
Masato Nakamura, Toru Aoyama, Keiichiro Ishibashi, Akihito Tsuji, Yasutaka Takinishi, Yoshiaki Shindo, Junichi Sakamoto, Koji Oba, Hideyuki Mishima
Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact
Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Naru Kondo, Naoya Nakagawa, Shinya Takahashi, Taijiro Sueda
Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma
Hui Zhang, Yan Guo, Yongsheng Song, Chao Shang
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
S. Kenneth Sy, Theresa D. Sweeney, Chunmei Ji, Ute Hoch, Michael A. Eldon
Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway
Ming-ming He, Dong-sheng Zhang, Feng Wang, Zi-xian Wang, Shu-qiang Yuan, Zhi-qiang Wang, Hui-yan Luo, Chao Ren, Miao-zhen Qiu, Ying Jin, De-shen Wang, Dong-liang Chen, Zhao-lei Zeng, Yu-hong Li, Yang-yang He, Yuan-tao Hao, Pi Guo, Feng-hua Wang, Yi-xin Zeng, Rui-hua Xu
Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma
Sung Won Lee, Hae Lim Lee, Nam Ik Han, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
Toshihiko Doi, Nozomu Fuse, Takayuki Yoshino, Takashi Kojima, Hideaki Bando, Hideaki Miyamoto, Masato Kaneko, Motonobu Osada, Atsushi Ohtsu
The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas
Young Saing Kim, Sung Yong Oh, Se-Il Go, Jung-Hun Kang, Inkeun Park, Haa-Na Song, Jun Ho Ji, In Gyu Hwang, Joung-Soon Jang
Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer
Takayuki Yoshino, Ichinosuke Hyodo, Tomohiro Nishina, Hiroyuki Narahara, Naotoshi Sugimoto, Kunihiro Yoshisue, Narikazu Boku
Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells
James Chun Yip Chan, Pei Shi Ong, Peirong Lim, Preben Xiang Long Teng, Eric Chun Yong Chan
LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
Shunji Takahashi, Takayuki Kobayashi, Junichi Tomomatsu, Yoshinori Ito, Hisanobu Oda, Tatsuhiro Kajitani, Tomoyuki Kakizume, Takeshi Tajima, Hiromi Takeuchi, Heiko Maacke, Taito Esaki
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor
Changhoon Yoo, Hyungwoo Cho, Min Jeong Song, Seung-Mo Hong, Kyu-pyo Kim, Heung-Moon Chang, Heejung Chae, Tae Won Kim, Yong Sang Hong, Min-Hee Ryu, Yoon-Koo Kang, Song Cheol Kim, Baek-Yeol Ryoo
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104)
Hironaga Satake, Masaaki Iwatsuki, Yoshikazu Uenosono, Takeshi Shiraishi, Hiroaki Tanioka, Hiroshi Saeki, Keishi Sugimachi, Dai Kitagawa, Mototsugu Shimokawa, Eiji Oki, Yasunori Emi, Yoshihiro Kakeji, Akihito Tsuji, Yoshito Akagi, Shoji Natsugoe, Hideo Baba, Yoshihiko Maehara
A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma
Margarita B. Belogurova, Zoryana P. Kizyma, Miklós Garami, Mónika Csóka, Michael J. Lamson, Anton Buchner, Peter Bias, Andreas Lammerich
Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer
Kyoichi Kaira, Yoshio Tomizawa, Hisao Imai, Reiko Sakurai, Masana Matsuura, Akihiro Yoshii, Mai Ochiai, Mie Kotake, Takeshi Ebara, Jun-ichi Saitoh, Noriaki Sunaga, Koichi Minato, Ryusei Saito, Takeshi Hisada
Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma
Ji Young Lee, Cheryn Song, Bum Sik Hong, Jun Hyuk Hong, Hanjong Ahn, Jae Lyun Lee
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium
Frank M. Balis, Patrick A. Thompson, Yael P. Mosse, Susan M. Blaney, Charles G. Minard, Brenda J. Weigel, Elizabeth Fox
Population pharmacokinetics of lenalidomide in multiple myeloma patients
Beatriz Guglieri-López, Alejandro Pérez-Pitarch, Dirk Jan A. R. Moes, Begoña Porta-Oltra, Mónica Climente-Martí, Henk Jan Guchelaar, Matilde Merino-Sanjuán
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies
Charles A. Kunos, Edward Chu, Jan H. Beumer, Mario Sznol, S. Percy Ivy
Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis
Hisao Imai, Kyoichi Kaira, Ichiro Naruse, Hideki Hayashi, Hirotoshi Iihara, Yutaro Kita, Naoki Mizusaki, Takayuki Asao, Yoshinori Itoh, Tadashi Sugiyama, Koichi Minato, Masanobu Yamada
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure
Kim Dao, Yimin Lu, Cody J. Peer, William D. Figg, Raphael Stadelmann, Michel Burnier, Thierry Buclin, Sebastien Kissling